Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial
Gary Middleton(University Hospitals Birmingham NHS Foundation Trust), John P. Neoptolemos(University of Liverpool), Stephen Falk(At Bristol), Jonathan Wadsley(Weston Park Cancer Centre), Richard Jackson(University of Liverpool), Srinivasan Madhusudan(University of Nottingham), Charlotte Rawcliffe(University of Liverpool), Paula Ghaneh(University of Liverpool), Daniel H. Palmer(University of Liverpool), Tamas Hickish(Southampton General Hospital), William Greenhalf(University of Liverpool), Nick Wadd(South Tees Hospitals NHS Foundation Trust), David Propper(St Bartholomew's Hospital), A.G. Evans(Princeton University), David Cunningham(Royal Marsden NHS Foundation Trust), Victoria Shaw(University of Liverpool), Pippa Corrie(University of Cambridge), Harpreet Wasan(Hammersmith Hospital), Juan W. Valle(Cancer Research UK Manchester Institute), Trevor F. Cox(University of Liverpool), Paul J. Ross(King's College Hospital NHS Foundation Trust), Fareeda Y. Coxon(Newcastle upon Tyne Hospitals NHS Foundation Trust), Fiona Campbell(University of Liverpool), Eithne Costello(University of Liverpool)
Cited by 73
Related Papers
Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
|New England Journal of Medicine|2008|2.3k
Spontaneous formation of ordered structures in thin films of metals supported on an elastomeric polymer
|Nature|1998|2.3k
Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial
|The Lancet|2017|1.9k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k